Viewing Study NCT02066532

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 9:56 PM
Ignite Modification Date: 2026-05-22 @ 1:47 PM
Study NCT ID: NCT02066532
Status: COMPLETED
Last Update Posted: 2023-08-24
First Post: 2014-02-18
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer
Sponsor: Dawn L. Hershman
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Metastatic Breast Cancer View
None Breast Carcinoma View
None HER-2 Positive Breast Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Breast Neoplasms View
None Breast Cancer View
None Breast Carcinoma View
None Breast tumors View
None Cancer of the Breast View
None Malignant tumor of the breast View
None HER2 positive View
None erythroblastosis virus oncogene B-2 (erbB-2) View
None Metastatic Breast Cancer View
None Secondary Breast Cancer View